An Open-Label, Single-Dose, Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) l1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years.

Trial Profile

An Open-Label, Single-Dose, Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) l1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 30 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 15 May 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.
    • 04 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top